News

Three Promising Blue-Chip Stocks for Upcoming Earnings Season

Three Promising Blue-Chip Stocks for Upcoming Earnings Season

Optimism Surrounding the New Earnings Season

As we approach a new earnings season, there are numerous reasons to feel hopeful about the economy's trajectory. While challenges remain, many investors are strategically considering their next steps amidst these uncertainties.

The expectation for many companies in the S&P 500 is an average year-over-year earnings growth of 5%. This projection carries both good and bad news.

The encouraging news is that growth expectations have seen positive changes recently, particularly in the technology sector. Yet, the anticipated growth rate appears considerably slower compared to previous years.

A significant factor influencing this deceleration is companies' wait for definitive updates regarding tariffs. Although the situation is becoming clearer, accurate forecasting remains a challenge for analysts and investors until all numbers are finalized.

The Appeal of Blue-Chip Companies

In light of this uncertainty, investors may find safety in large-cap, blue-chip companies. These firms are characterized by robust balance sheets, reliable cash flows, and significant pricing power.

Here are three blue-chip stocks that not only benefit from positive growth trends and effective management but are also predicted to exceed overall market earnings growth in the latter half of 2025.

1. Alphabet: A Resilient Tech Powerhouse

Alphabet (NASDAQ: GOOGL) has recently faced challenges, underperforming compared to some of its peers in the tech sector. A main concern is the influence of generative AI on its search operations.

This narrative will unfold over several years. However, in its recent quarterly earnings report, Alphabet showcased a remarkable 12% increase in revenue year-over-year, alongside a 49% surge in earnings per share (EPS). This robust growth was evident across all service divisions, notably through the rising popularity of YouTube.

Crucially, the company’s Google Cloud division continues to gain momentum, outperforming major competitors such as Amazon and Microsoft in terms of revenue growth rates.

Alphabet is also pursuing cutting-edge initiatives including autonomous driving technology via Waymo, developing AI chips, and venturing into quantum computing. Moreover, the company has committed to a significant share buyback program, further enhancing its financial appeal.

Analysts project a consensus price target of approximately $199.95 for GOOGL, indicating an upside of about 13%. This figure aligns closely with EPS growth projections of around 14.8%, proving its valuation attractive with a forward earnings ratio around 20x.

2. Eli Lilly: A Leader Amid Rising Competition

Eli Lilly (NYSE: LLY) emerged as one of the standout performers in the previous year, thanks to a select group of stocks riding a bullish wave. As the landscape broadens, LLY appears well-positioned for further growth.

With its successful GLP-1 drugs, including Mounjaro and Zepbound, Eli Lilly has established a lead in the pharmaceutical sector. The company is also developing an oral formulation of these treatments to address unmet patient needs.

Investors should keep an eye on Eli Lilly’s expansive pipeline, which encompasses prospective medications for Alzheimer’s and cancer treatments—segments that are expected to flourish over the next decade.

After peaking in the previous year, LLY stock has seen a decline of approximately 15%. Nevertheless, since reporting impressive quarterly earnings, showing year-over-year revenue and EPS growth of 45% and 29%, respectively, LLY has rebounded nearly 7%. Analysts anticipate earnings growth exceeding 34% next year, with a consensus price target of $1,012, suggesting potential gains of over 31%.

While LLY is trading at a premium compared to the overall market, it remains undervalued against its historical averages.

3. JPMorgan: A Steady Choice for Secure Investments

Bank stocks are often viewed as stable, and JPMorgan Chase (NYSE: JPM) is no exception. With a breathtaking total return exceeding 256% over the last five years, JPMorgan proves that stability can lead to exceptional results.

The banking sector has thrived on higher interest rates, contributing to substantial increases in net interest income. However, the market remains cautious as expectations of lower rates in the near future circulate.

Regardless of interest rate movements, JPMorgan's solid balance sheet positions it favorably. Should rates decrease, the bank could experience increased loan demand with minimized default risk.

Among the discussed stocks, JPM is projected to have the slowest earnings growth at about 7.2%, still surpassing the S&P average. This trend is common within bank stocks. Additionally, potential investors should consider the dividend yield, which stands at an appealing 1.92%.

Frequently Asked Questions

What are the main themes discussed in the article?

The article explores the optimism surrounding the upcoming earnings season, focusing on three significant blue-chip companies that are expected to perform well.

Which companies are highlighted as strong investment opportunities?

Alphabet, Eli Lilly, and JPMorgan are identified as top choices for investors looking for stable growth during the upcoming earnings season.

What growth rates are projected for these companies?

Alphabet and Eli Lilly are expected to demonstrate notable earnings growth, while JPMorgan's growth, although more modest, remains above the S&P average.

What should investors consider when approaching these stocks?

Investors are encouraged to examine each company's financial health, growth prospects, and market conditions before making investment decisions.

How does the broader economic situation impact these stocks?

The ongoing economic uncertainty and changes in interest rates can influence stock performance, making reliable companies like those mentioned more attractive during turbulent times.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 17

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 16

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 29

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 22

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 22

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 22

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 22

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 23

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 24

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

Asia Midday Update: Stock Market Movements and Trends

Updated Category News Views 234

Asia Midday Stock Market Insights During the recent stock market activity, the US stock market showed resilience despite facing renewed tariff discussions. Major indices experienced a breakout from previous consolidations, primarily driven by a significant 2.8% increase in Nvidia (NASDAQ: NVDA). This surge was notable as Nvidia achieved a remarkable milestone, being the...

Continue Reading
Fibocom Pushes AIoT Innovation at ElectroneX 2026

Updated Category News Views 11

What's the Buzz About Fibocom at ElectroneX? Some folks are really shaking things up over at ElectroneX 2026 in Sydney. Fibocom's out there flexing their latest AIoT wares, and the scene's ripe with promise. Under the catchy theme "Intelligent Connectivity for a Smarter World," you're seeing wireless solutions that scream innovation—speaking right to the heart of the...

Continue Reading
Transforming $100 into Significant Gains with Nike's Growth

Updated Category News Views 34

Transforming $100 into Significant Gains with Nike's Growth Nike (NYSE: NKE) has consistently delivered impressive performance in the stock market over the past two decades. With an annualized return of 11.56%, it has outperformed many other investments, showcasing its strong market presence and growth potential. As of now, Nike boasts a market capitalization of an...

Continue Reading
Modern Lion and Hyundai Card Partner to Transform Concerts

Updated Category News Views 60

Revolutionizing Concert Experiences with NFT Integration Modern Lion is embarking on a transformative journey by launching KONKRIT, an innovative platform for NFT-based ticketing, in partnership with Hyundai Card and NEAR Protocol. This collaboration is set to redefine how we experience concerts, paving the way for secure ticket purchases and enhanced event engagement....

Continue Reading
Verisk Analytics Faces Analyst Downgrades Following Q3 Report

Updated Category News Views 177

Verisk Analytics Reports Third Quarter Results Verisk Analytics, Inc. (NASDAQ:VRSK) has recently revealed its third-quarter financial performance, showcasing a mix of ups and downs that have caught the attention of analysts across the industry. Financial Performance Overview The company declared quarterly earnings of $1.72 per share, surpassing the consensus estimate by a...

Continue Reading